Posted by Michael Wonder on 05 Sep 2025
FDA approves expanded use of Vonvendi for von Willebrand disease, including for certain uses for children
5 September 2025 - The US FDA today approved expanded use of Vonvendi [von Willebrand factor (recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease and on-demand and treatment of bleeding episodes and perioperative use in children with von Willebrand disease.
Previously, Vonvendi was approved only for on demand treatment of bleeding episodes and peri-operative use in adults and preventative use only in adults with type 3 von Willebrand disease, the most serious type.
